Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia

Blood

Volumn 94, Issue 1, 1999, Pages 12-22

  Lo Coco, Francesco ^a   Diverio, Daniela ^b   Falini, Brunangelo ^b   Biondi, Andrea ^b   Nervi, Clara ^b   Pelicci, Pier Giuseppe ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; RETINOIC ACID;

ANTIBODY LABELING; BLOOD CLOTTING DISORDER; DIAGNOSTIC APPROACH ROUTE; GENE AMPLIFICATION; HUMAN; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW;

EID: 0033168322     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.1.12.413a44_12_22     Document Type: Review

References (119)

1. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF: Acute promyelocytic leukemia. Results of treatment with daunorubicin. Blood 41:489, 1973
2. Marty M, Ganem G, Fischer J, Flandrin G, Berger R, Schaison G, Degos L, Boiron M: Leucémie aigue promyélocitaire: Étude retrospective de 119 malades traités par daunorubicine. Nouv Rev Fran Hématol 26:371, 1984
3. Petti MC, Avvisati G, Amadori S, Baccarani M, Guarini AR, Papa G, Rosti GA, Tura S, Mandelli F: Acute promyelocytic leukemia: Clinical aspects and results of treatment in 62 patients. Haematologica 72:151, 1987
4. Sanz MA, Jarque I, Martin G, Lorenzo I, Martinez J, Rafecas J, Pastor E, Sayas MJ, Sanz G, Gomis F: Acute promyelocytic leukemia. Therapy results and prognostic factors. Cancer 61:7, 1988
5. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M, Spier C, Hanson C, Bitter M, Braziel R, Mills G, Welborn J, Williams W, Hewlett J, Willman C, Appelbaum FR: Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86:1717, 1995
6. Bernard J: History of promyelocytic leukemia. Leukemia 8:1, 1994 (suppl 2)
7. Kakizuka A, Miller WH, Umesono K, Warrell RP, Frankel SR, Murty VVVS, Dmitrovsky E, Evans RM: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARa with a novel putative transcription factor, PML. Cell 66:663, 1991
8. de Thé H, Lavau C, Marchio A, Chomienne C, Lanotte M, Degos L, Dejean A: The PML/RARa fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675, 1991
9. Alcalay M, Zangrilli D, Pandolfi PP, Longo L, Mencarelli A, Giacomucci A, Rocchi M, Biondi A, Rambaldi A, Lo Coco F, Diverio D, Donti E, Grignani F, Pelicci PG: Translocation breakpoint of acute promyelocytic leukemia lies within the retinoic acid receptor a locus. Proc Natl Acad Sci USA 88:1977, 1991
10. Huang ME, Yu-Chen Y, Shou-Rong C, Lu MX, Zhoa L, Gu LJ, Wang ZY: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567, 1988
11. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I Clinical results. Blood 76:1704, 1990
12. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E: Differentiation therapy for acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). N Engl J Med 324:1385, 1991
13. Grignani F, Fagioli M, Alcalay M, Longo L, Pandolfi PP, Donti E, Biondi A, Lo Coco F, Grignani F, Pelicci PG: Acute promyelocytic leukemia: from genetics to treatment. Blood 83:10, 1994
14. Chen S-J, Wang Z-Y, Chen Z: Acute promyelocytic leukemia: From clinic to molecular biology. Stem Cells 13:22, 1995
15. Warrell RP Jr: Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med 47:555, 1996
16. Wiernik PH, Gallagher RE, Tallman MS: Diagnosis and treatment of acute promyelocytic leukemia, in Wiernik PH, Canellos GP, Dutcher JP, Kyle RA (eds) Neoplastic Diseases of the Blood. New York, NY, Churchill Livingstone, 1996, p 353
17. Fenaux P, Chomienne C, Degos L: Acute promyelocytic leukemia: Biology and treatment. Semin Oncol 24:92, 1997
18. Slack JL: Recent advances in the biology and treatment of acute promyelocytic leukemia. Educational Book of the 34th Meeting of the American Society of Clinical Oncology. Los Angeles, CA, 1998, p 54
19. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F: Molecular remission in PML/RARa-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90:1014, 1997
20. Fenaux P, Chastang C, Sanz MA, Thomas X, Dombret H, Link H, Guerci A, Fegueux N, San Miguel J, Rayon C, Zittoun R, Gardin C, Maloisel F, Fey M, Travade P, Reiffers J, Stamatoulas A, Stoppa AM, Caillot D, Lefrère F, Hayat M, Castaigne S, Chomienne C, Degos L: ATRA followed by chemotherapy (CT) vs ATRA pul CT and the role of maintenance therapy in newly diagnosed acute promyelocytie leukemia (APL): First interim results of APL 93 trial. Blood 90:122a, 1997 (abstr, suppl 1)
21. Burnett AK, Goldstone AH, Gray RG, Wheatley K, on behalf of the UK MRC Adult Leukemia Working Party: All trans retinoic acid given concurrently with induction chemotherapy improves the outcome of APL: Results of the UK MRC ATRA trial. Blood 90:330a, 1997 (abstr, suppl 1)
22. Sanz MA, Martin G, Diaz-Mediavilla J: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 338:393, 1998
23. Frankel SR, Eardley A, Heller G, Berman E, Miller WH Jr, Dmitrovsky E, Warrell RP Jr: All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York Study. Ann Int Med 120:278, 1995
24. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15:483, 1997
25. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 337:1201, 1997
26. Asou N, Adachi J, Tamura J, Kanamuru S, Kageyama S, Hirakoa A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R for the Japan Adult Leukemia Study Group: Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 16:78, 1998
27. Sun GL, OuYang RR, Chen SJ, Gu LJ, Xie WY, Zhang FQ, Li XS, Zhong DH, Cai JR, Chen Z, Wang ZY, Lu JX, Huang LA, Qian ZC, Yu HQ, Wang YL: Treatment of APL with all-trans retinoic acid: A report of five-year experience. Chin J Cancer 11:125, 1993
28. Miller WH Jr, Kakizuka A, Frankel SR, Warrell RP Jr, De Blasio A, Levine K, Evans RM, Dmitrovsky E: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor a clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:2694, 1992
29. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Peschle C, Nicoletti I, Pelicci PG: The acute promyelocytic leukaemia specific PML/RARa fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423, 1993
30. Early E, Moore MAS, Kakizuka A, Nason-Burchenal K, Martin P, Evans RM, Dmitrovsky E: Transgenic expression of PML/RARa impairs myelopoiesis. Proc Natl Acad Sci USA 93:7900, 1996
31. He LZ, Tribioli C, Rivi R, Peruzzi D, Pelicci PG, Soares V, Cattoretti G, Pandolfi PP: Acute leukemia with promyelocytic features in PML/RARa transgenic mice. Proc Natl Acad Sci USA 1997 94:5302, 1997
32. Brown D, Scott K, Lagasse E, Weissman I, Alcalay M, Pelicci PG, Atwater S, Bishop M: A PML/RARa transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:2551, 1997
33. Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ: Altered myeloid development and acute leukemia in transgenic mice expressing PML/RARa under control of catepsin G regulatory sequences. Blood 89:376, 1997
34. Yoshida H, Kitamura K, Tanaka K, Omura S, Miyazaki T, Hachiya T, Ohno R, Naoe T: Accelerated degradation of PML-retinoic acid receptor a (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: Possible role of the proteasome pathway. Cancer Res 38:2945, 1996
35. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH Jr: The PML/RARa oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88:2826, 1996
36. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R: Caspases mediate retinoic acid induced degradation of the acute promyelocytic leukemia PML-RARa fusion protein. Blood 92:2244, 1998
37. Hong SH, David G, Wong CW, Dejean A, Privalsky ML: SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor a (RARa) and PLZF/RARa oncoproteins associated with acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:9028, 1997
38. Grignani F, DeMatteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir F, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG: Fusion proteins of the retinoic acid receptor-a recruit histone deacetylase in promyelocytic leukemia. Nature 391:815, 1998
39. Lin R, Nagy L, Inoue S, Shao W, Miller WH, Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 391:811, 1998
40. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP: Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126, 1998
41. Diverio D, Riccioni R, Mandelli F, Lo Coco F: The PML/RARa fusion gene in the diagnosis and monitoring of acute promyelocytic leukemia. Haematologica 80:155, 1995
42. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E: Establishing the presence of the t(15;17) in suspected acute promyelocytic leukemia: Cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 94:557, 1996
43. Dyck J, Warrell RP, Evans RM, Miller WH: Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RARa protein. Blood 86:862, 1995
44. Falini B, Flenghi L, Fagioli M, Lo Coco F, Cordone I, Diverio D, Biondi A, Raganelli D, Liso A, Martelli MF, Pileri S: Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the anti-PML monoclonal antibody PG-M3. Blood 90:4046, 1997
45. Borrow J, Goddard AD, Gibbons B, Katz F, Swirsky D, Fioretos T, Dube I, Winfield DA, Kingston J, Hagemejier A, Rees JKH, Lister TA, Solomon E: Diagnosis of acute promyelocytic leukemia by RT-PCR detection of PML/RARa and RARa/PML fusion transcripts. Br J Haematol 82:532, 1992
46. Biondi A, Rambaldi A, Pandolfi PP, Rossi V, Giudici G, Alcalay M, Lo Coco F, Diverio D, Pogliani EM, Lanzi EM, Mandelli F, Masera G, Barbui T, Pelicci PG: Molecular monitoring of the myl/RARa fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 80:492, 1992
47. Chang KS, Lu J, Wang G, Trujillo JM, Estey E, Cork A, Chu DT, Freireich EJ, Stass SA: The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene. Targets for the detection of minimal residual disease by polymerase chain reaction. Blood 79:554, 1992
48. Castaigne S, Balitrand N, de Thé H, Dejean A, Degos L, Chomienne C: A PML/retinoic receptor-a fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 79:3110, 1992
49. Lo Coco F, Diverio D, Pandolfi PP, Biondi A, Rossi V, Avvisati G, Rambaldi A, Arcese W, Petti MC, Meloni G, Mandelli F, Grignani F, Masera G, Barbui T, Pelicci PG: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 340:1437, 1992
50. Huang W, Sun G-L, Li X-S, Cao Q, Lu Y, Jang G-S, Zhang F-Q, Chai J-R, Wang Z-Y, Waxman S, Chen Z, Chen S-J: Acute promyelocytic leukemia: Clinical relevance of two major PML-RARa isoforms and detection of minimal residual disease by retrotranscriptasepolymerase chain reaction. Blood 82:1264, 1993
51. Miller WH Jr, Levine K, De Blasio A, Frankel SR, Dmitrovsky E, Warrell RP Jr: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction. Blood 82:1689, 1993
52. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi F, Lo Coco F: Early detection of relapse by prospective RT-PCR analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92:784, 1998
53. Lo Coco F, Diverio D, Petti MC, Avvisati G, Pogliani EM, Biondi A, Meloni G, Mandelli F: Therapy of minimal disease recurrence in acute promyelocytic leukemia. Br J Haematol 102:149a, 1998 (abstr)
54. Grimwade D, Rahman J, Goulden N, Kempsi H, Mastrangelo S, Veys P: Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second CR using all-trans retinoic acid. Br J Haematol 103:559, 1998
55. Ruthardt M, Testa U, Nervi C, Grignani F, Puccetti E, Peschle C, Pelicci PG: Opposite effects of the acute promyelocytic leukaemia PML/RARa and PLZF/RARa fusion proteins on retinoic acid signalling. Mol Cell Biol 17:4859, 1997
56. Rousselot P, Hardas B, Patel A, Guidez F, Gaken J, Castaigne S, Dejean A, de Thè H, Degos L, Farzaneh F, Chomienne C: The PML-RARa gene product of the (15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene 9:545, 1994
57. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10:940, 1996
58. Tsai S, Bartelmez S, Sitnicka E, Collins S: Lymphohematopoietic progenitors immortalized by a retroviral vector harboring a dominant-negative retinoic acid receptor can recapitulate lymphoid, myeloid, and erythroid development. Genes Dev 8:2831, 1994
59. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389:349, 1997
60. Rogaia D, Grignani F, Grignani F, Nicoletti I, Pelicci PG: The acute promyelocytic leukemia-specific PML/RAR alpha fusion protein reduces the frequency of commitment to apoptosis upon growth factor deprivation of GM-CSF-dependent myeloid cells. Leukemia 9:1467, 1995
61. Ferrucci PF, Grignani Fr, Pearson M, Fagioli M, Nicoletti I, Pelicci PG: Cell death induction by the acute promyelocytic leukemia-specific PML/RARa fusion protein. Proc Natl Acad Sci USA 94:10901, 1997
62. Koken MHM, Linares-Cruz G, Quignon F, Viron A, Chelbi-Alix MK, Sobczak-Thepot J, Juhlin L, Degos L, Calvo F, de The H: The PML growth-suppressor has an altered expression in human oncogenesis. Oncogene 10:1315, 1995
63. Liu JH, Mu ZM, Chang KS: PML suppresses oncogenic transformation of NIH/3T3 cells by activated neu. J Exp Med 181:1965, 1995
64. Mu Z-M, Chin K-V, Liu J-H, Lozano G, Chang K-S: PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol 14:6858, 1994
65. Fagioli M, Alcalay M, Tomassoni L, Ferrucci PF, Mencarelli A, Riganelli D, Grignani Fr, Pozzan T, Nicoletti I, Grignani F, Pelicci PG: Cooperation between the RING + B1-B2 and coiled-coil domains of PML is necessary for its effects on cell survival. Oncogene 16:2905, 1998
66. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP: Role of PML in cell growth and the retinoic acid pathway. Science 279:1547, 1998
67. Dyck JA, Maul GG, Miller WH, Chen JD, Kakizuka A, Evans RM: A novel macromolecular structure is a target of the promyelocyteretinoic acid receptor oncoprotein. Cell 76:333, 1994
68. Weis K, Rambaud S, Lavau C, Jansen J, Carvahlo T, Carmo-Fonseca M, Lamond A, Dejean A: Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells. Cell 76:345, 1994
69. Koken MHM, Puvion-Dutilleul F, Guillemin MC, Viron A, Linares-Cruz G, Stuurman N, De Jong L, Szostecki C, Calvo F, Chomienne C, Degos L, Puvion E, de Thé H: The t(15;17) translocation alters a nuclear body in a retinoic acid-reversible fashion. EMBO J 13:1073, 1994
70. Ruthardt M, Orleth A, Tomassoni L, Puccetti E, Riganelli D, Alcalay M, Mannucci R, Nicoletti I, Grignani F, Fagioli M, Pelicci PG: The acute promyelocytic leukemia specific PML and PLZF protein localize to adjacent and functionally distinct nuclear bodies. Oncogene 16:1945, 1998
71. Licht JD, Chomienne C, Goy A, Chen A, Scott AA, Head DR, Michaux JL, Wu Y, Deblasio A, Miller WH Jr, Zelenetz AD, Willman CL, Chen Z, Chen SJ, Zelent A, Macintyre E, Veil A, Cortes J, Kantarjian H, Waxman S: Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood 85:1083, 1995
72. Brunning RD, McKenna RW: Tumors of the bone marrow. Atlas of Tumor Pathology. Washington, DC, Armed Forces Institute of Pathology (AFIP), Fascicle 9, 1994, p 45
73. Berger R, Bernheim A, Daniel MT, Valensi F, Flandrin G: Cytological types of mitoses and chromosome abnormalities in acute leukemia. Leuk Res 7:221, 1983
74. Hiorns LR, Min T, Swansbury GJ, Zelent A, Dyer MJS, Catovsky D: Interstitial insertion of retinoic acid receptor-a gene in acute promyelocytic leukemia with normal chromosomes 15 and 17. Blood 83:2946, 1994
75. Grimwade D, Gorman P, Duprez E, Howe K, Langabeer S, Oliver F, Walkner H, Culligan D, Waters J, Pomfret M, Goldstone A, Burnett A, Freemont P, Sheer D, Solomon E: Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood 90:4876, 1997
76. Miura I, Nishinari T, Hashimoto K, Nimura T, Miura S, Miura AB: Translocation (8;17) (p21;q21), a possible variant of t(15;17) in acute promyelocytic leukemia. Cancer Genet Cytogen 72:75, 1994
77. Wells RA, Hummel JL, De Koven A, Zipursky A, Kirby M, Dube I, Kamel-Reid S: A new variant translocation in acute promyelocytic leukemia: Molecular characterization and clinical correlation. Leukemia 10:735, 1996
78. Cigudosa JC, Calasanz MJ, Odero MD, Marin J, Bengoechea E, Gullon A: A variant t(14;17) in acute promyelocytic leukemia. Cancer Genet Cytogenet 80:160, 1995
79. Osella P, Wyandt H, Vosburgh E, Milunsky A: Report of a variant t(1;15;17) (p36;q22;q21.1) in a patient with acute promyelocytic leukemia. Cancer Genet Cytogenet 57:201, 1991
80. Galieni P, Marotta G, Vessichelli F, Diverio D, Minoletti F, Bucalossi A, Lo Coco F, Lauria F: Variant t(1;15;17) (q23;q22;q23) in a case of acute promyelocytic leukemia. Leukemia 10:1658, 1996
81. Schoch C, Haase D, Haferlach T, Freund M, Link H, Lengfelder E, Loffler H, Buchner T, Fonatsch C: Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15;17) (q22;q21): a report on 50 patients. Br J Haematol 94:493, 1996
82. Slack JL, Arthur DC, Lawrence D, Mrozek K, Mayor RJ, Davey FR, Tantravahi R, Pettenati MJ, Bigner S, Carroll AJ, Rao KW, Schiffer CA, Bloomfield CD: Secondary cytogenetic changes in acute promyelocytic leukemia: Prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene. A Cancer and Leukemia Group B study. J Clin Oncol 15:1786, 1997
83. Hiorns LR, Swansbury GJ, Metha J, Min T, Dainton MG, Trevelean J, Powles RL, Catovsky D: Additional chromosome abnormalities confer poor prognosis in acute promyelocytic leukemia. Br J Haematol 96:314, 1997
84. Chen SJ, Zhu Y-J, Dong S, Huang W, Chen Y, Xiang W-M, Zhang L, Li X-S, Qian G-Q, Wang Z-Y, Chen Z, Larsen C-J, Berger R: Rearrangements in the second intron of the RARA gene are present in a large majority of patients with acute promyelocytic leukemia and are used as molecular marker for retinoic acid-induced leukemic cell differentiation. Blood 78:2696, 1991
85. Diverio D, Lo Coco F, D'Adamo F, Biondi A, Fagioli M, Grignani F, Rambaldi A, Rossi V, Avvisati G, Petti MC, Testi AM, Liso V, Specchia G, Fioritoni G, Recchia A, Frassoni F, Ciolli S, Pelicci PG: Identification of DNA rearrangements at the RARa locus in all patients with acute promyelocytic leukemia and mapping of APL breakpoints within the RARa second intron. Blood 70:3331, 1992
86. Biondi A, Rambaldi A, Alcalay M, Pandolfi PP, Lo Coco F, Diverio D, Rossi V, Mencarelli A, Longo L, Zangrilli D, Masera G, Barbui T, Mandelli F, Grignani F, Pelicci PG: RARa gene rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. Blood 77:1418, 1991
87. Flenghi L, Fagioli M, Tomassoni L, Pileri S, Gambacorta M, Pacini R, Grignani F, Casini T, Ferrucci PF, Martelli MF, Pelicci PG: Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product. Immunocytochemical evidence for high PML expression on activated macrophages and endothelial cells. Blood 85:1871, 1995
88. Fukutani H, Naoe T, Ohno R, Yoshida H, Kiyoi H, Miyawaki S, Morishita H, Sano F, Kamibayashi H, Matsue K, Miyake T, Hasegawa S, Ueda Y, Kato Y, Kobayashi H, Shimazaki C, Kobayashi M, Kurane R, Sakota H, Masaki K, Wakayama T, Tohyama K, Nonaka Y, Natori H: Prognostic significance of the RT-PCR assay of PML/RARa transcripts in acute promyelocytic leukemia. Leukemia 9:588, 1995
89. Seale JRC, Varma S, Swirsky DM, Pandolfi PP, Goldman JM, Cross NCP: Quantification of PML/RARa transcripts in acute promyelocytic leukemia: Explanation for lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukemia-specific mRNA by alpha interferon. Br J Haematol 95:95, 1996
90. Diverio D, Riccioni R, Pistilli A, Buffolino S, Avvisati G, Mandelli F, Lo Coco F: Improved rapid detection of the PML/RARa fusion gene in acute promyelocytic leukemia. Leukemia 10:1214, 1996
91. Lion T: Control genes in the reverse transcriptase-polymerase chain reaction assay. Leukemia 11:872, 1997
92. Guglielmi C, Martelli MP, Diverio D, Fenu S, Vegna ML, Cantu-Rajnoldi A, Cocito MG, Del Vecchi L, Tabilio A, Avvisati G, Basso G, Lo Coco F: Clinical and biological relevance of immunophenotype in acute promyelocytic leukemia. Br J Haematol 102:1035, 1998
93. Claxton DF, Reading CL, Nagarian L, Tsujimoto Y, Anderson BS, Estey E, Cork A, Huh YO, Trujillo J, Deisseroth AB: Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. Blood 80:582, 1992
94. Maslak P, Miller WH Jr, Heller G, Scheinberg DA, Dmitrovsky E, Warrell RP Jr: CD2 expression and PML/RARa transcripts in acute promyelocytic leukemia. Blood 81:1666, 1993
95. Biondi A, Luciano A, Bassan R, Mininni D, Specchia G, Lanzi E, Castagna S, Cantu-Rajnoldi A, Liso V, Masera G, Barbui T, Rambaldi A: CD2 expression in acute promyelocytic leukemia is associated with microgranular morphology (FAB M3V) but not with any PML gene breakpoint. Leukemia 9:1461, 1995
96. Vahdat L, Maslak P, Miller WH, Eardley A, Heller G, Scheinberg DA, Warrell RP: Early mortality and retinoic acid syndrome in acute promyelocytic leukemia: Impact of leucocytosis, low-dose chemotherapy, PML/RARa isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 84:3843, 1994
97. Fukutani H, Naoe T, Ohno R, Yoshida H, Miyawaki S, Shimazaki C, Miyake T, Nakayama Y, Kobayashi H, Goto S, Takeshita A, Kobayashi S, Kato Y, Shiraishi K, Sasada M, Ohtake S, Murakami H, Kobayashi M, Endo N, Shindo H, Matsushita K, Hasegawa S, Tsuij K, Ueda Y, Tominaga N, Furuya H, Inoue Y, Takeuchi Y, Morishita H, Iida H: Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia 9:1478, 1995
98. Gallagher RE, Li Y-P, Rao S, Paietta E, Andersen J, Etkind P, Bennet JM, Tollman MS, Wiernik PH: Characterization of acute promyelocytic leukemia cases with PML/RARa break/fusion sites in PML exon 6: identification of a subgroup with decreased in vitro responsiveness to all-trans retinoic acid. Blood 86:1540, 1995
99. Gallagher RE, Willman CL, Slack JL, Andersen J, Li Y, Viswanatha D, Bloomfield CD, Applebaum FR, Schiffer CA, Tallman MS, Wiernik PH: Association of PML/RARa fusion mRNA type with pre-treatment characteristics but not treatment outcome in acute promyelocytic leukemia: An intergroup molecular study. Blood 90:1656, 1997
100. Kane JR, Head DR, Balazs L, Hulshof MG, Motroni TA, Raimondi SC, Carroll AJ, Behma FG, Krance RA, Shurtleff SA, Downing JR: Molecular analysis of the PML/RARa chimeric gene in pediatric acute promyelocytic leukemia. Leukemia 10:1296, 1996
101. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH, on behalf of the MRC Adult Leukaemia Working Party: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Results of the randomized MRC trial. Blood 1999 (in press)
102. Benedetti L, Levin AA, Scicchitano BM, Grignani F, Allenby G, Diverio D, Lo Coco F, Avvisati G, Ruthardt M, Adamo S, Pelicci PG, Nervi C: Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood 90:1175, 1997
103. Diverio D, Pandolfi PP, Rossi V, Biondi A, Pelicci PG, Lo Coco F: Monitoring of treatment outcome in acute promyelocytic leukemia. Leukemia 10:1214, 1994
104. Diverio D, Pandolfi PP, Biondi A, Avvisati G, Petti MC, Mandelli F, Pelicci PG, Lo Coco F: Absence of RT-PCR detectable residual disease in acute promyelocytic leukemia in long term remission. Blood 85:3556, 1993
105. Martinelli G, Remiddi C, Visani G, Farabegoli P, Testoni N, Zaccaria A, Manfroi S, Cenacchi A, Russo D, Bandini G, Amabile M, De Vivo A, Tura S: Molecular analysis of PML/RARa fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute promyelocytic leukaemia patients. Br J Haematol 90:966, 1995
106. Levine K, DeBlasio A, Miller WH Jr: Molecular diagnosis and monitoring of acute promyelocytic leukemia treated with retinoic acid. Leukemia 8:S116, 1994 (suppl 1)
107. Ikeda K, Sasaki K, Tasaka T, Nagai M, Kawanishi K, Takahara J, Irino S: PML/RARa fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome. Int J Hematol 60:197, 1994
108. Koller E, Karlic H, Krieger O, Mistrik M, Michlmayr G, Gadner H, Lutz D, Heinz R, Pitterman E: Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia. Ann Hematol 70:75, 1995
109. Korninger L, Knobl P, Laczika K, Mustafa S, Quehenberger P, Schwarzinger I, Lechner K, Jaeger U, Mannhalter C: PML/RARα PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months. Br J Haematol 88:427, 1994
110. Lackzika K, Mitterbauer G, Korninger L, Knobl P, Scharzinger I, Kapiotis S, Haas OA, Kyrle PA, Pont J, Oehler L: Rapid achievement of PML/RARα PCR negativity by combined treatment with all trans retinoic acid and chemotherapy in acute promyelocytic leukemia: A pilot study. Leukemia 8:1, 1994
111. Grimwade D, Howe K, Langabeer S, Burnett AK, Goldstone A, Solomon E: Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation of PML-RARα and RARα-PML assessment in patients who ultimately relapse. Leukemia 10:61, 1996
112. Perego RA, Marenco P, Bianchi C, Cairoli R, Urbano M, Nosari AM, Muti G, Morra E, Del Monte U: PML/RARα transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation. Leukemia 10:207, 1996
113. Roman J, Martin C, Torres A, Jimenez MA, Andres O, Flores R, De la Torre MJ, Sanchez J, Serrano J, Falcon M: Absence of detectable PML/RARα fusion transcripts in long-term remission patients after bone marrow transplantation for acute promyelocytic leukemia. Bone Marrow Transplant 17:679, 1997
114. Tobal K, Saunders MJ, Grey MR, Liu Yin JA: Persistence of RARα-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukemia. Br J Haematol 90:615, 1995
115. Bolufer P, Barragan E, Sanz MA, Martin G, Bornstein R, Colomer D, Delgado MD, Gonzalez M, Marugan I, Roman J, Gomez MT, Anguita E, Diverio D, Chomienne C, Briz M: Preliminary experience in external quality control of RT-PCR PML/RARα detection in promyelocytic leukemia. Leukemia 12:2024, 1998
116. Alcalay M, Zangrilli D, Fagioli M, Pandolfi PP, Mencarelli A, Lo Coco F, Biondi A, Grignani F, Pelicci PG: Expression pattern of the RARα-PML fusion gene in acute promyelocytic leukemia. Proc Natl Acad Sci USA 89:4840, 1992
117. Wang J, Hoshino T, Redner RL, Kajigaya S, Liu JM: ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc Natl Acad Sci USA 95:10860, 1998
118. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA: Aberrant recruitment of the nuclear corepressor histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185, 1998
119. Giles RH, Peters DJ, Breuning MH: Conjunction dysfunction: CBP/p300 in human disease. Trends Genet 14:178, 1998